MétaCan
Menu
← Back to cohort

Multicentre phase II trial of combination neoadjuvant hormone therapy and weekly docetaxel prior to radical prostatectomy in high risk localized prostate cancer (CUOG-P01a)

2004· article· en· W2249185594 on OpenAlexaffabout
M.E. Gleave, K. N., Larry Goldenberg, Joseph L. Chin, Eric Winquist, Laurence Klotz, Fred Saad, John Trachtenberg

Bibliographic record

VenueJournal of Clinical Oncology · 2004
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsLondon Health Sciences CentreVancouver General HospitalSunnybrook Health Science Centre
Fundersnot available
KeywordsMedicineDocetaxelProstatectomyProstate cancerOncologyUrologyProstateHormone therapyInternal medicineHormonal therapyCancerGynecologyBreast cancer

Abstract

fetched live from OpenAlex

4635 Background: Docetaxel is active for hormone refractory prostate cancer (HRPC) and may have additive effects if combined with androgen ablation in hormone naïve disease. Potential beneficial or adverse effects of combination vs sequential chemo-hormonal regimens are poorly defined. The objective of this trial was to assess the tolerability and pathologic effects (including high-throughput transcriptional and immunohistochemical bioprofiling) of 6 months of combined androgen ablation + docetaxel in men with high risk localized prostate cancer prior to radical prostatectomy. Methods: In a Phase II multicentre, single arm, open-label study men with newly diagnosed previously untreated clinically localized high-risk disease received androgen ablation (buserelin acetate 6.3 mg q 8 weeks x 3, + anti-androgen for 4 weeks) + weekly docetaxel (35 mg/m2 iv weekly x 6 q 8 weeks for 3 cycles). Results: 72 men with a mean age of 55 years (range 45–74) and mean serum PSA of 17.8 μg/L (range 2.5–66) were enrolled at 6 sites across Canada. Baseline prognostic factors included 51% cT2 and 38% cT3; 32% Gleason 7, 32% Gleason 8, and 27% Gleason 9; PSA <10 in 44%, 10–20 μg/L in 25%, and >20 μg/L in 31%. Eight patients discontinued study therapy for > grade 3 toxicity (n=5), withdrawal of consent (n=1), or identification of metastatic disease (n=2). 64 patients completed protocol therapy and surgery. 38 (59%) were pathological T2N0, including 2 complete responders (P-0) and 10 with residual microfoci of cancer. 26 (41%) were pT3, including 7 with seminal vesicle invasion (pT3c), and 4 T3N1. Positive surgical margins were identified in 17 (27%), including 5 pT2 and 12 pT3 tumors. Conclusion: Combined androgen ablation + weekly docetaxel is reasonably well tolerated and results in significant pathologic responses and lower than expected positive surgical margins for this high-risk group. Tissue microarray construction and transcriptional profiling are underway to define treatment-induced changes in gene expression. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis; Novartis; OncoGenex Abbott; Avenits; Novartis Aventis

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.015

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.004
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.083
GPT teacher head0.478
Teacher spread0.394 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2004
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicProstate Cancer Treatment and Research→French-language works237,207→